» Articles » PMID: 37955868

Renal Cortical Glucose Uptake Is Decreased in Insulin Resistance and Correlates Inversely With Serum Free-fatty Acids

Abstract

Context: Studies on human renal metabolism are scanty. Nowadays, functional imaging allows the characterization of renal metabolism in a noninvasive manner. We have recently demonstrated that fluorodeoxyglucose F18 (18F FDG) positron emission tomography can be used to analyze renal glucose uptake (GU) rates, and that the renal cortex is an insulin-sensitive tissue.

Objective: To confirm that renal GU is decreased in people with obesity and to test whether circulating metabolites are related to renal GU.

Design, Setting And Participants: Eighteen people with obesity and 18 nonobese controls were studied with [18F]FDG positron emission tomography during insulin clamp. Renal scans were obtained ∼60 minutes after [18F]FDG injection. Renal GU was measured using fractional uptake rate and after correcting for residual intratubular [18F]FDG. Circulating metabolites were measured using high-throughput proton nuclear magnetic resonance metabolomics.

Results: Cortical GU was higher in healthy nonobese controls compared with people with obesity (4.7 [3.4-5.6] vs 3.1 [2.2-4.3], P = .004, respectively), and it associated positively with the degree of insulin sensitivity (M value) (r = 0.42, P = .01). Moreover, cortical GU was inversely associated with circulating β-OH-butyrate (r = -0.58, P = .009), acetoacetate (r = -0.48, P = .008), citrate (r = -0.44, P = .01), and free fatty acids (r = -0.68, P < .0001), even when accounting for the M value. On the contrary, medullary GU was not associated with any clinical parameters.

Conclusion: These data confirm differences in renal cortical GU between people with obesity and healthy nonobese controls. Moreover, the negative correlations between renal cortex GU and free fatty acids, ketone bodies, and citrate are suggestive of substrate competition in the renal cortex.

Citing Articles

Risk of Insulin Resistance in 44,939 Spanish Healthcare Workers: Association with Sociodemographic Variables and Healthy Habits.

Tarraga Marcos P, Lopez-Gonzalez A, Martinez-Almoyna Rifa E, Paublini Oliveira H, Martorell Sanchez C, Tarraga Lopez P Diseases. 2025; 13(2).

PMID: 39997040 PMC: 11854469. DOI: 10.3390/diseases13020033.


Free Fatty Acids and Free Fatty Acid Receptors: Role in Regulating Arterial Function.

Yu F, Zong B, Ji L, Sun P, Jia D, Wang R Int J Mol Sci. 2024; 25(14).

PMID: 39063095 PMC: 11277118. DOI: 10.3390/ijms25147853.

References
1.
Wasik A, Lehtonen S . Glucose Transporters in Diabetic Kidney Disease-Friends or Foes?. Front Endocrinol (Lausanne). 2018; 9:155. PMC: 5900043. DOI: 10.3389/fendo.2018.00155. View

2.
UNDERWOOD A, Newsholme E . Some properties of phosphofructokinase from kidney cortex and their relation to glucose metabolism. Biochem J. 1967; 104(1):296-9. PMC: 1270576. DOI: 10.1042/bj1040296. View

3.
Welch W . Intrarenal oxygen and hypertension. Clin Exp Pharmacol Physiol. 2006; 33(10):1002-5. DOI: 10.1111/j.1440-1681.2006.04478.x. View

4.
Gnudi L, Coward R, Long D . Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms. Trends Endocrinol Metab. 2016; 27(11):820-830. DOI: 10.1016/j.tem.2016.07.002. View

5.
Susztak K, Ciccone E, McCue P, Sharma K, Bottinger E . Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2005; 2(2):e45. PMC: 549593. DOI: 10.1371/journal.pmed.0020045. View